Page 2,732«..1020..2,7312,7322,7332,734..2,7402,750..»

Stem Cell Treatment with Danny Glover – Video

Posted: June 19, 2012 at 8:11 pm

18-06-2012 18:01 Stem Cell Treatment at is exactly what actor Danny Glover received during his visit. Danny knows the positive impact stem cell therapy has on many different diseases and illnesses. Danny did his own stem cell research and found that the American Stem Cell & Anti Aging Center met his strict standards of medical stem cell care. If you have any questions visit the website and contact us right on the home page contact form. You can also call 800-442-1519. Visit the website at http

Read more here:
Stem Cell Treatment with Danny Glover - Video

Posted in Stem Cell Therapy | Comments Off on Stem Cell Treatment with Danny Glover – Video

Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial

Posted: June 19, 2012 at 8:10 pm

ROCKVILLE, Md., June 19, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient to receive stem cell transplantation in both regions of the spinal cord has been treated in the ongoing Phase I trial of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This is also the 16th patient to be treated in the trial altogether and the first patient returning to the trial for a second treatment. In this treatment, the patient received five injections in the cervical (upper back) region of the spinal cord, in addition to the ten he received previously in the lumbar (lower back) region of the spine, for a total of 15 injections. This is the highest number of injections in the trial so far. Patient 16 is also the first patient in the world to receive stem cell transplants in both the lumbar and cervical regions of the spinal cord in an FDA-approved trial. Two additional previously-treated patients are expected to return to the trial this summer in this cohort, provided they continue to meet the inclusion requirements. The trial is taking place at Emory University Hospital in Atlanta, Georgia.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"Transplanting the first of the returning patients represents a major milestone in the trial," said Dr. Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "The ability to safely administer multiple dosings to these patients is a key enabling step in administering the maximum safe dose. Not only are we dosing patients for a second time in this cohort, we are now dosing in both the lumbar and cervical regions of the spinal cord for the first time, where the stem cell therapy could support both walking and breathing."

About the Trial

The Phase I trial to assess the safety of Neuralstem's spinal cord neural stem cells and intraspinal transplantation method in ALS patients has been underway since January 2010. The trial is designed to enroll up to 18 patients. The first 12 patients were each transplanted in the lumbar (lower back) region of the spine, beginning with non-ambulatory and advancing to ambulatory cohorts.

The trial then advanced to transplantation in the cervical (upper back) region of the spine. The first cohort of three was treated in the cervical region only. The current cohort of three will receive injections in both the cervical and lumbar regions of the spinal cord. In an amendment to the trial design, The Food and Drug Administration (FDA) approved the return of previously-treated patients to this cohort. The first of these returning patients was just treated. The entire 18-patient trial concludes six months after the final surgery.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include CTE (chronic traumatic encephalopathy), Alzheimer's disease, anxiety, and memory disorders.

Read more:
Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial

Posted in Stem Cell Therapy | Comments Off on Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial

French scientists revive stem cells of dead people

Posted: June 19, 2012 at 5:16 pm

French scientists revive stem cells of dead people

A group from the Pasteur Institute was able to reactivate muscle stem cells from deceased persons after 17 days, which functioned normally after transplant...

by Fabrice Chretien

French scientists were able to revive stem cells of muscle and bone marrow from persons who were already dead for 17 days, reports the journal Nature Communications in a paper released on Wednesday (13th) in France.

A team of researchers from the Pasteur Institute demonstrated that it is possible to reactivate the muscle stem cells from human cadavers and transplant them to make new ones born in perfect condition.

The scientists found that these cells did not die with the person. That's because they reduced their activity to a minimum and, after discarding the mitochondria (small bodies that help with breathing), were in a state of hibernation.

Thus, cells could survive even in an environment so hostile, without oxygen and in the middle of an acid bath, as well as in the case of a muscle injury, "sleeping and waiting out the storm," as Professor Fabrice Chrtien affirmed to the newspaper Libration.

"This reserve of stem cells could serve to make bone marrow transplants used to treat leukemia and blood diseases, among other conditions. They could also address the lack of donors," said Chretien, who led the study alongside researcher, Shahragim Tajbakhsh.

Despite the advances that have also been successfully tested in rats, the experiment showed an increase of one type of substance called ROS, which, in turn, has an incompatibility with the cells and genome, Professor Jean-Marc Lemaitre pointed out to the paper, Le Figaro. Due to this fact, the study still needs to determine whether these new cells, even in perfect condition, can hide still undetected malformations.

Translated from the Portuguese version by:

View post:
French scientists revive stem cells of dead people

Posted in Stem Cell Videos | Comments Off on French scientists revive stem cells of dead people

New method generates cardiac muscle patches from stem cells

Posted: June 19, 2012 at 5:16 pm

Public release date: 18-Jun-2012 [ | E-mail | Share ]

Contact: Shantell M. Kirkendoll smkirk@umich.edu 734-764-2220 University of Michigan Health System

A cutting-edge method developed at the University of Michigan Center for Arrhythmia Research successfully uses stem cells to create heart cells capable of mimicking the heart's crucial squeezing action.

The cells displayed activity similar to most people's resting heart rate. At 60 beats per minute, the rhythmic electrical impulse transmission of the engineered cells in the U-M study is 10 times faster than in most other reported stem cell studies.

An image of the electrically stimulated cardiac cells is displayed on the cover of the current issue of Circulation Research, a publication of the American Heart Association.

For those suffering from common, but deadly, heart diseases, stem cell biology represents a new medical frontier.

The U-M team of researchers is using stem cells in hopes of helping the 2.5 million people with an arrhythmia, an irregularity in the heart's electrical impulses that can impair the heart's ability to pump blood.

"To date, the majority of studies using induced pluripotent stem cell-derived cardiac muscle cells have focused on single cell functional analysis," says senior author Todd J. Herron, Ph.D., an assistant research professor in the Departments of Internal Medicine and Molecular & Integrative Physiology at the U-M.

"For potential stem cell-based cardiac regeneration therapies for heart disease, however, it is critical to develop multi-cellular tissue like constructs that beat as a single unit," says Herron.

Their objective, working with researchers at the University of Oxford, Imperial College and University of Wisconsin, included developing a bioengineering approach, using stem cells generated from skin biopsies, which can be used to create large numbers of cardiac muscle cells that can transmit uniform electrical impulses and function as a unit.

Link:
New method generates cardiac muscle patches from stem cells

Posted in Stem Cell Videos | Comments Off on New method generates cardiac muscle patches from stem cells

Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

Posted: June 19, 2012 at 5:16 pm

17-06-2012 23:59 Gary B Stem Cell Therapy for CMT Part 2 - For more info. visit

Go here to read the rest:
Stem Cell Therapy for CMT-Gary B-part 2.mp4 - Video

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

European researchers crack embryonic stem cells mystery

Posted: June 19, 2012 at 5:16 pm

European researchers discover that embryonic stem cell properties are impacted by the laboratory conditions used to grow them.

In their groundbreaking study, a European team of researchers evaluated embryonic stem cells grown in a pure undifferentiated state. The use of next generation sequencing technology enabled them to analyse gene expression (i.e. transcriptome) and chromatin modifications (i.e. epigenome). The study is presented in the journal Cell. The results pinpoint key differences between pure stem cells and embryonic stem cells grown in laboratory settings.

What allows embryonic stem cells to stay pluripotent? Researchers have been investigating this mystery for some time. Now a team of researchers from Germany, the Netherlands and the United Kingdom provide key answers, giving us information we need to know about how cells are controlled and what is the optimal way to grow them. The findings overturn previous reports suggesting that embryonic stem cells are both unstable and primed to differentiate. This information could help lead to the development of new and effective treatments.

Researchers from Nijmegen Centre for Molecular Life Sciences (NCMLS) and Radboud University in the Netherlands, as well as the Wellcome Trust Centre for Stem Cell Research, Stem Cell Institute and the University of Cambridge in the United Kingdom, and Technische Universitt Dresden in Germany confirmed that transcriptome analysis allows scientists to identify which genes are turned on or off inside the cells. The gene's level of activity is also calculated through this method. Meanwhile, epigenome analysis provides researchers insight into how genes are controlled. This study went a step further by unlocking the mystery of how embryonic stem cells maintain their pluripotency, which experts describe as the capacity to make various cell types.

Through this study, researchers obtained key reference information in their quest to create a novel kind of human pluripotent stem cell equivalent to mouse embryonic stem cells. According to the team, the data represents the ground state of pluripotency.

Commenting on the results of the study, EUROSYSTEM ('European consortium for systematic stem cell biology') coordinator Austin Smith said: "These findings show how much we are still learning about stem cells. They also point to an underlying difference between true embryonic stem cells isolated from mice and the currently available human stem cells which are less pure and more variable."

More information: Marks, H., et al. 'The Transcriptional and Epigenomic Foundations of Ground State Pluripotency', Cell, 2012, 149(3), 590-604. doi:10.1016/j.cell.2012.03.026

Journal reference: Cell

Provided by CORDIS

Read this article:
European researchers crack embryonic stem cells mystery

Posted in Stem Cell Research | Comments Off on European researchers crack embryonic stem cells mystery

Cryopraxis, Sponsor of Stem Cell Research is Represented at Bio2012 in Boston

Posted: June 19, 2012 at 5:16 pm

RIO DE JANEIRO--(BUSINESS WIRE)--

Cryopraxis established in 2001 as the pioneer private umbilical cord blood bank in Brazil will be present at Bio 2012 in Boston. Eduardo Cruz, chairman of the board, will be a speaker at the Brazilian break-out session speaking about The Brazilian Biotechnology Sector and showing the results of the company's commitment to R&D. Cryopraxis has already collected and processed more than 25000 cord blood units (CBU) and is actively involved in several R&D projects in Brazil and abroad.

A spin-off of Cryopraxis, Cellpraxis, has recently finished one of the world's first cell therapy project clinical trials in Brazil: ReACT. ReACT is a stem cell formulation. This regenerative medicine pioneer product aims on treating an orphan disease condition called refractory angina. Refractory angina patients suffer from untreatable severe chest pain and the results of the clinical trial in a 5 years follow up proved ReACT to positively interfere in the course of the pathology. Most of the individuals treated experienced relief in pain and better quality of life. ReACT will be presented at Bio2012 as an example of Brazil's dynamic biotechnology research.

Cryopraxis is accredited by the American Association of Blood Bank since 2009.

According to Tatiana Lima, Technical Director at Cryopraxis, "extensive training and strict adherence to good laboratory practices are basic principles in Cryopraxis' corporate strategy." Janaina Machado, cell lab director describes the company's primary mission: "maximizing safety and efficiency of collection procedures to make sure our clients get what they look for: the highest quality standards."

Cryopraxis is part of Axis Biotec (www.axisbiotec.com.br) and it has the largest biological cryogenic storage facility in Brazil and one of the largest in the World. It is the largest umbilical cord blood bank in Brazil. The company is involved in several research projects in Brazil and abroad.For more information, visitwww.cryopraxis.com.brand http://www.cellpraxis.com

The rest is here:
Cryopraxis, Sponsor of Stem Cell Research is Represented at Bio2012 in Boston

Posted in Stem Cell Research | Comments Off on Cryopraxis, Sponsor of Stem Cell Research is Represented at Bio2012 in Boston

Stem cell market to reach $322 million by 2017

Posted: June 19, 2012 at 5:16 pm

2011 saw the stem cell market earn revenues of $148.4 million in 2011 and this is forecast to reach $322 million by 2017. The segments covered include: bio-imaging and microscopy, cell biology tools, immunochemical, molecular biology tools, and protein biochemistry tools.

The US is one of the major stem cell markets in the world, and the country has been witnessing a significant level of positive growth over the past few years. The US stem cell market was estimated to reach around $830 Million in 2010, up from $500 Million in 2009.

This market growth can be attributed to a number of supporting factors, such as huge investment, strong demand, and rising disease incidences. Forecasters have predicted that these factors will lead to the US stem cell market generating revenues of $3 billion by 2013.

A key step forward for the market has been the stem cell regulations in a few countries allowing the use of certain cell lines. In some countries such as France, for instance, stem cell regulations are being renewed for the procurement and use of stem cells.

Standardised research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments. Regenerative medicine is seen as an area with high future potential, as countries need ways to cope with the burden of an aging population.

Stem cell research is very dynamic with research trends, focus, and approaches evolving extremely rapidly. The tool market has to quickly adapt to these challenges and develop innovative tools that address and accelerate research accomplishments.

Organisations such as the International Society for Stem Cell Research (ISSCR) publish recommended guidelines on working with stem cells, but these are not binding. Governments must therefore come together to determine a standardised framework for innovative medical research, in order that positive results and long-term follow-up data can be produced to solidify the reputation and investment potential of the regenerative medicine market.

For more information on the stem cell market, see the latest research: Stem Cell Market Report

Follow us on Twitter @CandMResearch

About: Companiesandmarkets.com is a UK based organisation, home to one of the worlds largest databases of market research reports and company profiles from leading global publishers and industry analysts. Multinational brands across major industries rely daily on companiesandmarkets.com for strategic market research and incisive company profiles. Call +44 (0)203 086 8600.

See the original post:
Stem cell market to reach $322 million by 2017

Posted in Stem Cell Research | Comments Off on Stem cell market to reach $322 million by 2017

Anti-cocaine vaccine described in Human Gene Therapy Journal

Posted: June 19, 2012 at 4:25 am

Public release date: 18-Jun-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 18, 2012A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

"This is a very novel approach for addressing the huge medical problem of cocaine addiction," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

In the article "AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior," (http://online.liebertpub.com/doi/pdfplus/10.1089/hum.2011.178) a team of researchers from Weill Cornell Medical College (New York, NY), The Scripps Research Institute (La Jolla, CA), and Cornell University (Ithaca, NY) used a virus-based delivery vehicle in mice to transfer a gene that produces a protein capable of binding to cocaine present in the blood, preventing the cocaine from crossing into the brain. The protein is a monoclonal antibody that sequesters cocaine, making the vaccinated mice resistant to the drug's effects. Whereas unvaccinated mice exhibited hyperactivity when exposed to intravenous cocaine, the immunized mice showed no effects, according to authors Jonathan Rosenberg, et al.

###

About the Journal

Human Gene Therapy (http://www.liebertpub.com/hum), the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of contents and a free sample issue may be viewed online at the Human Gene Therapy website (http://www.liebertpub.com/hum).

About the Publisher

Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website (http://www.liebertpub.com).

Read more:
Anti-cocaine vaccine described in Human Gene Therapy Journal

Posted in Gene therapy | Comments Off on Anti-cocaine vaccine described in Human Gene Therapy Journal

Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

Posted: June 19, 2012 at 4:24 am

17-06-2012 23:59 Gary B Stem Cell Therapy for CMT Part 2 - For more info. visit

Read more from the original source:
Stem Cell Therapy for CMT-Gary B-part 2.mp4 - Video

Posted in Cell Therapy | Comments Off on Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

Page 2,732«..1020..2,7312,7322,7332,734..2,7402,750..»